🚀 VC round data is live in beta, check it out!
Alkermes Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alkermes and similar public comparables like Scholar Rock, Gan and Lee, Xenon Pharmaceuticals, TG Therapeutics and more.
Alkermes Overview
About Alkermes
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Founded
2011
HQ
Employees
1.8K
Website
Sectors
Financials (LTM)
EV
$5B
Alkermes Financials
Alkermes reported last 12-month revenue of $2B and EBITDA of $392M.
In the same LTM period, Alkermes generated $1B in gross profit, $392M in EBITDA, and $147M in net income.
Revenue (LTM)
Alkermes P&L
In the most recent fiscal year, Alkermes reported revenue of $1B and EBITDA of $394M.
Alkermes expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | $392M | XXX | $394M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $147M | XXX | $242M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 16% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alkermes Stock Performance
Alkermes has current market cap of $6B, and enterprise value of $5B.
Market Cap Evolution
Alkermes' stock price is $34.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $6B | 2.2% | XXX | XXX | XXX | $1.45 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlkermes Valuation Multiples
Alkermes trades at 3.3x EV/Revenue multiple, and 13.3x EV/EBITDA.
EV / Revenue (LTM)
Alkermes Financial Valuation Multiples
As of April 18, 2026, Alkermes has market cap of $6B and EV of $5B.
Equity research analysts estimate Alkermes' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alkermes has a P/E ratio of 39.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 13.3x | XXX | 13.3x | XXX | XXX | XXX |
| EV/EBIT | 31.4x | XXX | 20.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | 4.1x | XXX | XXX | XXX |
| P/E | 39.1x | XXX | 23.7x | XXX | XXX | XXX |
| EV/FCF | 14.9x | XXX | 10.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alkermes Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alkermes Margins & Growth Rates
Alkermes' revenue in the last 12 month grew by 16%.
Alkermes' revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.6M for the same period.
Alkermes' rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alkermes' rule of X is 76% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Alkermes Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | (1%) | XXX | (1%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 76% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 49% | XXX | 48% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alkermes Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alkermes | XXX | XXX | XXX | XXX | XXX | XXX |
| Scholar Rock | XXX | XXX | XXX | XXX | XXX | XXX |
| Gan and Lee | XXX | XXX | XXX | XXX | XXX | XXX |
| Xenon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| TG Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Henlius Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alkermes M&A Activity
Alkermes acquired XXX companies to date.
Last acquisition by Alkermes was on XXXXXXXX, XXXXX. Alkermes acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alkermes
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlkermes Investment Activity
Alkermes invested in XXX companies to date.
Alkermes made its latest investment on XXXXXXXX, XXXXX. Alkermes invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alkermes
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alkermes
| When was Alkermes founded? | Alkermes was founded in 2011. |
| Where is Alkermes headquartered? | Alkermes is headquartered in United States. |
| How many employees does Alkermes have? | As of today, Alkermes has over 1K employees. |
| Who is the CEO of Alkermes? | Alkermes' CEO is Richard F. Pops. |
| Is Alkermes publicly listed? | Yes, Alkermes is a public company listed on Nasdaq. |
| What is the stock symbol of Alkermes? | Alkermes trades under ALKS ticker. |
| When did Alkermes go public? | Alkermes went public in 1991. |
| Who are competitors of Alkermes? | Alkermes main competitors are Scholar Rock, Gan and Lee, Xenon Pharmaceuticals, TG Therapeutics. |
| What is the current market cap of Alkermes? | Alkermes' current market cap is $6B. |
| What is the current revenue of Alkermes? | Alkermes' last 12 months revenue is $2B. |
| What is the current revenue growth of Alkermes? | Alkermes revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Alkermes? | Current revenue multiple of Alkermes is 3.3x. |
| Is Alkermes profitable? | Yes, Alkermes is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alkermes? | Alkermes' last 12 months EBITDA is $392M. |
| What is Alkermes' EBITDA margin? | Alkermes' last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Alkermes? | Current EBITDA multiple of Alkermes is 13.3x. |
| What is the current FCF of Alkermes? | Alkermes' last 12 months FCF is $351M. |
| What is Alkermes' FCF margin? | Alkermes' last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of Alkermes? | Current FCF multiple of Alkermes is 14.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.